Fairmount Funds Management LLC
- SEC CIK
- 0001802528
In the past year, 6 open-market purchase filings worth $69.6M and 5 sale filings worth $1.20B.
Current role at each company
- KRSA Korsana Biosciences, Inc.Director, 10% Owneras of Sep 10, 2026
- APGE Apogee Therapeutics, Inc.Directoras of Sep 3, 2026
- CBIO Crescent Biopharma, Inc.Director, 10% Owneras of Jul 20, 2026
- ORKA Oruka Therapeutics, Inc.Director, 10% Owneras of Jul 1, 2026
- SYRE Spyre Therapeutics, Inc.Directoras of Jun 23, 2026
Show 6 more companies
- JBIO Jade Biosciences, Inc.Director, 10% Owneras of Jun 11, 2026
- VRDN Viridian Therapeutics, Inc.Director, 10% Owneras of May 13, 2026
- ZBIO Zenas BioPharma, Inc.Directoras of Apr 1, 2026
- COGT Cogent Biosciences, Inc.Directoras of Mar 31, 2026
- DMRA Damora Therapeutics, Inc.Director, 10% Owneras of Mar 25, 2026
- DNTH Dianthus Therapeutics, Inc.Directoras of Oct 1, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- $69.6M
- 6 filings
- Sold
- $1.20B
- 5 filings
- Net
- −$1.13B
- Bought minus sold
- Companies
- 7
- With open-market trades
Trades
Every Form 4 that lists Fairmount Funds Management LLC as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CBIO Crescent Biopharma, Inc.
Director, 10% Owner4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 (view filing)5:30 PM ET | Jul 16 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +853.5K | $14.50 | +$12.4M | +31.1%3.60M after | |
| Jul 20, 2026 (view filing)5:30 PM ET | Jul 16 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +525.9K | $14.50 | +$7.62M | –2.29M after | Derivative |
| Dec 8, 2025 (view filing)4:30 PM ET | Dec 4 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +1.36M | $13.41 | +$18.2M | +98.0%2.75M after | |
| Dec 8, 2025 (view filing)4:30 PM ET | Dec 4 | 4 days | Harwin Peter Evan and 3 othersDirector, 10% Owner | PPurchase | +131.4K | $13.41 | +$1.76M | –1.77M after | Derivative |
ORKA Oruka Therapeutics, Inc.
Director, 10% Owner1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 (view filing)9:30 PM ET | Jul 1 | Same day | Harwin Peter Evan and 4 othersDirector, 10% Owner | SSale | −3.55M | $84.43 | −$300.0M | −75.8%1.13M after |
SYRE Spyre Therapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 23, 2026 (view filing)9:56 PM ET | Jun 23 | Same day | Harwin Peter Evan and 3 othersDirector | SSale | −4.68M | $85.31 | −$399.7M | −100.0%0 after |
VRDN Viridian Therapeutics, Inc.
Director, 10% Owner6 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 (view filing)4:31 PM ET | May 11 | 2 days | Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% Owner | PPurchase | +1.18M | $17.00 | +$20.0M | +30.1%5.09M after | |
| Oct 27, 2025 (view filing)4:30 PM ET | Oct 23 | 4 days | Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% Owner | PPurchase | +454.5K | $22.00 | +$10.0M | +13.1%3.91M after | |
| Sep 17, 2024 (view filing)9:00 PM ET | Sep 13 | 4 days | Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% Owner | PPurchase | +1.60M | $18.75 | +$30.0M | +86.7%3.45M after | |
| Jan 24, 2024 (view filing)6:44 PM ET | Jan 22 | 2 days | Fairmount Healthcare Fund L.P. and 4 othersDirector, Other: See Remarks | PPurchase | +476.2K | $21.00 | +$10.0M | +34.9%1.84M after | |
| Aug 19, 2022 (view filing)4:32 PM ET | Aug 17 | 2 days | Fairmount Healthcare Fund L.P. and 4 othersDirector, 10% Owner | PPurchase | +425.5K | $23.50 | +$10.0M | +45.4%1.36M after | |
| Sep 23, 2021 (view filing)9:30 AM ET | Sep 21 | 2 days | Fairmount Healthcare Fund L.P. and 4 othersDirector, Other: See Remarks | PPurchase | +909.0K | $11.00 | +$10.0M | +3,109.5%938.2K after |
ZBIO Zenas BioPharma, Inc.
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2026 (view filing)4:30 PM ET | Mar 31 | 1 day | Harwin Peter Evan and 3 othersDirector | PPurchase | +150.0K | $20.00 | +$3.00M | +6.8%2.36M after | |
| Oct 9, 2025 (view filing)4:15 PM ET | Oct 7 | 2 days | Harwin Peter Evan and 3 othersDirector | PPurchase | +316.2K | $19.00 | +$6.01M | +16.7%2.21M after | |
| Sep 17, 2024 (view filing)8:56 PM ET | Sep 16 | 1 day | Harwin Peter Evan and 3 othersDirector | PPurchase | +300.0K | $17.00 | +$5.10M | +18.8%1.89M after | Amended |
COGT Cogent Biosciences, Inc.
Director5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 (view filing) | Mar 31 | Same day | Fairmount Funds Management LLCDirector | SSale | −7.00M | $34.66 | −$242.6M | −56.0%5.50M after | |
| Jan 22, 2026 (view filing) | Jan 22 | Same day | Fairmount Funds Management LLCDirector | SSale | −3.50M | $36.40 | −$127.4M | −38.9%5.50M after | |
| Jul 14, 2025 (view filing) | Jul 10 | 4 days | Fairmount Funds Management LLCDirector | PPurchase | +2.78M | $9.00 | +$25.0M | +44.6%9.00M after | |
| Jun 13, 2023 (view filing) | Jun 9 | 4 days | Fairmount Funds Management LLC10% Owner, Other: See Remarks | PPurchase | +800.0K | $12.00 | +$9.60M | +32.4%3.27M after | |
| Jun 21, 2022 (view filing) | Jun 16 | 5 days | Fairmount Funds Management LLC10% Owner, Other: See Remarks | PPurchase | +1.20M | $8.25 | +$9.90M | +94.3%2.47M after |
APGE Apogee Therapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 22, 2026 (view filing)8:07 PM ET | Jan 22 | Same day | Harwin Peter Evan and 3 othersDirector | SSale | −1.75M | $76.30 | −$133.5M | −85.4%298.6K after | |
| Jul 17, 2023 (view filing)8:00 PM ET | Jul 13 | 4 days | Harwin Peter Evan and 5 othersDirector | PPurchase | +2.94M | $17.00 | +$50.0M | New position892.5K after | 3 lots |
DNTH Dianthus Therapeutics, Inc.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 3, 2023 (view filing)4:00 PM ET | Sep 29 | 4 days | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +24.7K | $13.63 | +$336.3K | +1.3%1.93M after | |
| Sep 28, 2023 (view filing)5:09 PM ET | Sep 26 | 2 days | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +30.0K | $13.15 | +$394.5K | +1.6%1.90M after | |
| Sep 21, 2023 (view filing)4:23 PM ET | Sep 19 | 2 days | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +30.0K | $13.20 | +$396.0K | +1.6%1.87M after | |
| Sep 13, 2023 (view filing)9:17 PM ET | Sep 12-13 | 1 day | Harwin Peter Evan and 2 othersDirector, 10% Owner | PPurchase | +24.3K | $11.20 | +$271.7K | +1.3%1.84M after | 2 lots |